Saving lives by reducing in-hospital mortality from sepsis and other acute inflammatory processes
Sepsis is the leading cause of in-hospital death. According to the WHO, sepsis affects more than 50 million people every year, causing the death of more than 11 million people. Almost half of them are children. Dr. Pelegrín’s group found that 80% of the patients’ monocytes developed in the first 24 hours an inability to activate the nlrp3 inflammasome and that this condition anticipated an unfavorable, even fatal evolution of this subgroup of patients. Our purpose is to reduce these deaths, as well as the immense suffering, and the gigantic expense due to ICU bed occupancy associated with them.
We have successfully completed the clinical proof of concept with the support of the European Research Council demonstrating that we can identify patients with sepsis and forecast their evolution with maximum specificity and with greater sensitivity and much faster than current systems. By the end of 2021 we have reached a technological readiness level (TRL) 4 and are moving on to the next steps so as to build a leadership position upon our current advantage in this field.
After analyzing the market studies and the field survey, we are currently working on the microfluidics of what we expect to be the first compact device for in vitro diagnosis of abdominal sepsis, prognosis and stratification of patients that uses specific oligomers related to the activation or not of the nlrp3 inflammasome. (More information in Company).
We are granted the international patent (PCT) WO 2020/182964 A1 and have applied for national phases in the European Union, Switzerland, Israel, Canada and the United States.
Doctor Pelegrín Vivancos
Deputy Scientific Director of the Murcian Institute of Biosanitary Research (IMIB) and Principal Investigator of its Molecular Inflammation Group. Professor of Immunology at University of Murcia as Distinguished Researcher “Beatriz Galindo”. Tokyo University of Science Presidential Award. Author of more than 100 high-impact scientific publications as prestigious as Cell, Immunity, Nature Immunology, Science Advances or Nature Chemical Biology.
As one of the scientific authorities on inflammasomes, its work in this field and other related ones, 9822 citations, h-index 51, index i10 84, places Viva In Vitro in a position of scientific-technological leadership to build its competitive advantage upon.
Experienced CEO and board of directors member, he has been committed with the success of this project for years now. MBA, specialized in mergers and acquisitions in the bio-health industry, as in the incorporation, venture capital funding and launching of spinoffs. He has executed joint development and marketing agreements on four continents and is considered an expert in open innovation. He has advised corporations and governmental bodies on novel technologies valuation, and have been coordinating committees of experts, mainly in biotechnology and biomedical technologies, for more than two decades.
Previous to Viva In Vitro, his last missions were related to fields such as fNIRS and AI-based early-stage diagnostics systems, CAR-T cells-based novel therapies, nanosensors national industry development (abroad, on a World Bank-funded mission) or nanotech solutions for drug delivery.
Reducing sepsis mortality: the company Viva In Vitro Diagnostics, promoted by Vincle Capital, is getting one step closer to its goal
Sepsis is the leading cause of hospital mortality as it causes around eleven million deaths a year. It also implies an unparalleled economic burden due
Today we received the visit of private investors to know the first spinoff of the Murcian Institute of Bio-health Research (IMIB, by its initials in
Welcome to our news page. After years of work and dedication to give this project a corporate shape, Pablo Pelegrín, Carlos García-Palenciano, María Fuensanta-Martínez, on